P/B
2,9
Niagen Bioscience
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
$235.8M
Market Cap • 9/28/2026
2000
(26 years)
Founded
2008
(18 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
1,8
P/EBITDA
31
P/OCF
39,6
P/FCF
41,6
P/E
16,6
BVPS
1
EPS
0,2
Market Cap
Market Cap
235,8M
EV
171,4M
EV/Revenue
1,3
EV/EBITDA
22,5
EV/EBIT
25,8
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
2%
Total Yield
2%
Payout
0%
Retained Earnings
-157,2M
Profitability
Gross Margin
64,2%
EBITDA Margin
5,9%
EBIT Margin
5,1%
Net Margin
10,8%
D&A/EBITDA
0%
R&D/Revenue
5%
Capex/Revenue
0,2%
Capex/D&A
28,2%
Capex/OCF
4,6%
SBC/OCF
116,7%
% PPE
2,9%
% Goodwill
0%
ROE
19%
ROIC
34,9%
Growth
CAGR Revenue 5Y
15,8%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
6,5
Quick Ratio
5
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!